Skip to main content
Advertisement
Advertisement
AMRX
AMRX logo
Amneal Pharmaceuticals, Inc. Class A Common Stock
21.12
USD
Sponsored
-0.27
-1.26%
Nov 20, 15:59 UTC -5
Closed
exchange

After-Market

21.45

+0.33
+1.56%

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Earnings

AMRX Earnings Reports

Positive Surprise Ratio

AMRX beat 30 of 44 last estimates.

68%

Next Report

Date of Next Report
Feb 25, 2027
Estimate for Q4 26 (Revenue/ EPS)
$860.29M
/
$0.24
Implied change from Q3 26 (Revenue/ EPS)
-0.28%
/
-7.69%
Implied change from Q4 25 (Revenue/ EPS)
+5.65%
/
+14.29%

Amneal Pharmaceuticals, Inc. Class A Common Stock earnings per share and revenue

On Nov 03, 2026, AMRX reported earnings of 0.26 USD per share (EPS) for Q3 26, beating the estimate of 0.23 USD, resulting in a 9.34% surprise. Revenue reached 862.68 million, compared to an expected 832.18 million, with a 3.67% difference. The market reacted with a -1.13% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.24 USD, with revenue projected to reach 860.29 million USD, implying an decrease of -7.69% EPS, and decrease of -0.28% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%
logo
Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%
logo
Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%
logo
Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%
logo
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%
logo
Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%
logo
Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%
logo
Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%
logo
Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%
logo
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
For Q3 2026, Amneal Pharmaceuticals, Inc. Class A Common Stock reported EPS of $0.26, beating estimates by 9.34%, and revenue of $862.68M, 3.67% above expectations.
The stock price moved down -1.13%, changed from $20.44 before the earnings release to $20.21 the day after.
The next earning report is scheduled for Feb 25, 2027.
Based on -- analysts, Amneal Pharmaceuticals, Inc. Class A Common Stock is expected to report EPS of $0.24 and revenue of $860.29M for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement